In the past week, EVH stock has gone down by -17.92%, with a monthly decline of -6.44% and a quarterly plunge of -59.25%. The volatility ratio for the week is 9.19%, and the volatility levels for the last 30 days are 5.88% for Evolent Health Inc The simple moving average for the last 20 days is -10.09% for EVH stock, with a simple moving average of -54.06% for the last 200 days.
Is It Worth Investing in Evolent Health Inc (NYSE: EVH) Right Now?
The 36-month beta value for EVH is also noteworthy at 1.45. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for EVH is 112.74M, and at present, short sellers hold a 9.04% of that float. The average trading volume of EVH on January 22, 2025 was 2.75M shares.
EVH) stock’s latest price update
The stock price of Evolent Health Inc (NYSE: EVH) has surged by 1.70 when compared to previous closing price of 10.00, but the company has seen a -17.92% decline in its stock price over the last five trading sessions. https://thefly.com reported 2025-01-15 that Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company’s 2025 guidance range coming in “significantly below consensus,” the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02.
Analysts’ Opinion of EVH
Many brokerage firms have already submitted their reports for EVH stocks, with Needham repeating the rating for EVH by listing it as a “Buy.” The predicted price for EVH in the upcoming period, according to Needham is $15 based on the research report published on January 10, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see EVH reach a price target of $29, previously predicting the price at $36. The rating they have provided for EVH stocks is “Buy” according to the report published on December 03rd, 2024.
Stephens gave a rating of “Equal-Weight” to EVH, setting the target price at $16 in the report published on November 08th of the previous year.
EVH Trading at -17.22% from the 50-Day Moving Average
After a stumble in the market that brought EVH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.94% of loss for the given period.
Volatility was left at 5.88%, however, over the last 30 days, the volatility rate increased by 9.19%, as shares sank -5.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.85% lower at present.
During the last 5 trading sessions, EVH fell by -17.92%, which changed the moving average for the period of 200-days by -66.25% in comparison to the 20-day moving average, which settled at $11.31. In addition, Evolent Health Inc saw -9.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVH starting from McCarthy Daniel Joseph, who sale 23,693 shares at the price of $30.89 back on Aug 22 ’24. After this action, McCarthy Daniel Joseph now owns 198,809 shares of Evolent Health Inc, valued at $731,790 using the latest closing price.
McCarthy Daniel Joseph, the PRESIDENT of Evolent Health Inc, sale 10,469 shares at $32.38 during a trade that took place back on Aug 23 ’24, which means that McCarthy Daniel Joseph is holding 188,340 shares at $339,008 based on the most recent closing price.
Stock Fundamentals for EVH
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.14 for the gross margin
The net margin for Evolent Health Inc stands at -0.03. The total capital return value is set at -0.01. Equity return is now at value -6.77, with -2.79 for asset returns.
Based on Evolent Health Inc (EVH), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.61. The interest coverage ratio of the stock is -0.74.
Currently, EBITDA for the company is -24.79 million with net debt to EBITDA at 8.29. When we switch over and look at the enterprise to sales, we see a ratio of 0.7. The receivables turnover for the company is 5.85for trailing twelve months and the total asset turnover is 0.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In summary, Evolent Health Inc (EVH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
